State of the ACTG Network

Judith Currier, MD
Co-PI and Network Chair
June 21, 2018
Completed Accrual

- 5263 KS Treatment
- 5278s Pk sub-studies of 5263 and 5264
- 5320 Hep C cohort
- 5329 HCT GT1 AbbVie
- 5332s Mechanistic sub-study REPRIEVE
- 5361s PREPARE sub-study REPRIEVE
- 5312 first cohort completed
Completed Follow-up

• 5315 Romidepsin
• 5335s Liver biopsy sub-study 5329
• 5337 Sirolimus
• 5350 Visbiome Probiotic
• 5336 Ruxolitinib
Opened and Close(er) to Opening

- 5366 Tamoxifen and Vorinistat (Women only)
- 5360 MinMon (Hep C)
- 5369 Gag conserved element therapeutic vaccine
- 5378 VRC01LS Single dose
- 5359 LA ART
- 5300B Phoenix
- 5356 Linezolid for MDR TB
In Development

- 5377 Tri-specific BNab
- 5375 Emergency Contraception with EFV and TB Rx
- 5376 Etonogestrel Implant DDI
- 5372 DDI DTG/Rifapentine
- 5373 INH Mono-resistant TB
- 5381 Obs DTG roll-out
- 5379 B-HIVE HBV vaccine
- 5380 PURGE-C (Acute Hep C)
- 5382 REP 2139-Mg Hep B cure
- 5364 Combination BNabs
- 5370 REGN2810 Anti-PD1 Ab
- 5368 Anti PD1 Ab for Hep B
- 5363 CVC for CVD
- 5362 Clofazimine for DS TB
- 5357 VRC01 + LA CAB
- 5355 CMV Vaccine

* Started development prior to July 2017
Proposals: PR, DACs, NWCS and DR

- Approved
  - 14 Proposals (PR)
  - 2 DACS
  - 11 DR
  - 16 NWCS

- Submitted by people “outside” the ACTG Network
  - 15 PR
  - 4 DACS
  - 17 NWCS
  - 6 DR
Accrual June 2017-May 2018

- 5314 participants enrolled
  - 3226 Interventional Trials (includes 2023 in REPRIEVE)
  - 2088 Observational and sub-studies
- 1765 US sites
- 3549 International Sites
Rolling Accrual

Rolling Monthly Accrual, Last 12 Months

<table>
<thead>
<tr>
<th>End Month</th>
<th>Actual</th>
</tr>
</thead>
<tbody>
<tr>
<td>June</td>
<td>3815</td>
</tr>
<tr>
<td>July</td>
<td>4018</td>
</tr>
<tr>
<td>Aug</td>
<td>4249</td>
</tr>
<tr>
<td>Sep</td>
<td>4389</td>
</tr>
<tr>
<td>Oct</td>
<td>4595</td>
</tr>
<tr>
<td>Nov</td>
<td>4829</td>
</tr>
<tr>
<td>Dec</td>
<td>5009</td>
</tr>
<tr>
<td>Jan-18</td>
<td>5308</td>
</tr>
<tr>
<td>Feb</td>
<td>5390</td>
</tr>
<tr>
<td>Mar</td>
<td>5447</td>
</tr>
<tr>
<td>Apr</td>
<td>5438</td>
</tr>
<tr>
<td>May</td>
<td>5314</td>
</tr>
</tbody>
</table>
Abstracts and Publications

• 49 Abstracts presented
• 56 Manuscripts published
  • AIDS (9)
  • CID (8)
  • JID (7)
  • JAIDS (4)
  • Plos Path (2)
  • Science (1)
New Initiatives

• Protocol Chair support will start when concept approved to help support young investigators and allow effort to complete development more quickly (12/1/18)

• Communications Working Group Established in the AEC
  • To promote dissemination of results and openings of our studies
  • Podcasts of protocol chairs planned to discuss new studies opening
  • Development of lay summaries of all papers published
  • Improved access to publications on our website

• Lab Retreat held June 5-6th to improve integration of specialty labs into our scientific agenda
The next 4 days…

• Plenary sessions to showcase data from completed trials
• Awards to recognize important contributions to the group
• Think Tanks, Business Sessions and Symposia to generate discussion and seek and engagement on the scientific agenda
• New Investigator Workshop- an introduction to working in the ACTG
• Lab Symposium to highlight new horizons in lab research
• Trainings for several new studies
• Support committee meetings- discover what these important groups do
• Get involved, pack a lunch and enjoy- we need you!!